HC Deb 18 January 1993 vol 217 cc74-5W
Mr. Morley

To ask the Minister of Agriculture, Fisheries and Food what representations he has received from organisations representing rabbit breeders on myxomatosis vaccine.

Mr. Soames

A number of representations have been received from organisations representing rabbit breeders, and from individuals owning rabbits, expressing concern that no myxomatosis vaccine is currently available in the United Kingdom. I share this concern and can confirm that applications to licence such vaccines, including one received recently, will be assessed as rapidly as possible.

Mr. Morley

To ask the Minister of Agriculture, Fisheries and Food whether suitable vaccines can be imported for myxomatosis and viral haemorrhagic disease in rabbits; and what steps his Department has taken to assist in making such vaccines available to vets.

Mr. Soames

No veterinary vaccine may be imported into or marketed in the United Kingdom without a product licence. The veterinary medicines directorate will assess any applications for such licences for myxomatosis or viral haemorrhagic disease vaccines as rapidly as possible.

Mr. Morley

To ask the Minister of Agriculture, Fisheries and Food if he will establish a fund to compensate owners for loss or damage to domestic and show rabbits as a consequence of myxomatosis.

Mr. Soames

It is not Government policy to offer compensation in such circumstances.

Mr. Morley

To ask the Minister of Agriculture, Fisheries and Food, pursuant to his answer to the hon. Member for Faversham (Sir R. Moate) of 8 June 1992,Official Report, column 15, if he will make a statement on the current position on myxomatosis vaccine.

Mr. Soames

No myxomatosis vaccine is currently licensed in the United Kingdom. However, the veterinary medicines directorate has recently received from Intervet (UK) Ltd. an application to licence such a vaccine. The data supporting the applications are being assessed as rapidly as possible against the standard Medicines Act criteria of safety, quality and efficacy.

Forward to